Next, we wanted to determine whether targeting ERα could block the metabolic and proliferative effects of estrogens in PCa by using ERα-positive breast cancer drugs, such as the pure anti-estrogen fulvestrant and SERMs (tamoxifen, raloxifene, and toremifene). The gene discussed is ESR1; the disease is breast carcinoma.